Samalizumab

Samalizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD200
Clinical data
ATC code none
Identifiers
CAS Number 1073059-33-2 N
ChemSpider none
UNII 64EUX713G6 N
Chemical and physical data
Formula C6542H10086N1702O2102S46
Molar mass 147.7 kg/mol
 NYesY (what is this?)  (verify)

Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]

Samalizumab was developed by Alexion Pharmaceuticals.

References

  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.


This article is issued from Wikipedia - version of the 9/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.